A 13-year-old girl presented with pelvic pain and imaging revealed a large right ovarian cystic mass. Histologic examination showed a malignant myxoid tumor with chicken-wire vasculature characteristic of a myxoid liposarcoma. The morphologic appearances were supported by the presence of the rearrangement of the CHOP gene demonstrated by interphase fluorescent in situ hybridization. There was no evidence that this tumor represented metastatic disease. To the best of our knowledge, primary ovarian myxoid liposarcoma has not been previously reported in the English literature. We present the case and briefly discuss the differential diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PGP.0b013e3181c03fc9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: The cancer/testis antigen New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is a promising target in myxoid/round cell liposarcoma (MRCLS).
Methods: In this pilot study, we assessed the adoptive T-cell therapy NY-ESO-1cT letetresgene autoleucel (lete-cel) in patients with human leukocyte antigen (HLA)-A*02:01-, HLA-A*02:05-, and/or HLA-A*02:06-positive advanced/metastatic NY-ESO-1-expressing MRCLS. Patients underwent a reduced-dose (cohort 1) or standard-dose (cohort 2) lymphodepletion regimen (LDR).
From Images to Insights: Multimodal Imaging for Cardiac Metastases in Myxoid Liposarcomas.
JACC Case Rep
December 2024
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.
A Pericardial Mass in a Patient With Recurrent Liposarcoma.
JACC Case Rep
December 2024
Cardiology Hospital, XXI Century National Medical Center, Mexican Social Security Institute, Mexico City, Mexico.
Pericardial and cardiac masses in patients with established malignant neoplasms represent a diagnostic and therapeutic challenge. We present the case of a 66-year-old woman with history of myxoid liposarcoma of the left thigh who had an unexpected recurrence in the pericardium 12 years later.
View Article and Find Full Text PDFSurvival and prognostic factors among different types of liposarcomas based on SEER database.
Sci Rep
January 2025
Orthopedics Department, The First Affiliated Hospital of Army Medical University, Chongqing, China.
The aim of this study is to elucidate the disparities in survival and risk factors among different subtypes of liposarcoma, through analysis of epidemiological and prognostic data. The study cohort consisted of 12,822 patients diagnosed with liposarcoma in the United States between 2000 and 2021, whose data were retrieved from the Surveillance, Epidemiology, and End Results (SEER) program. The prognosis for different subtypes of liposarcoma and the associated factors such as age, tumor stage, intervention, gender, tumor grade, location, size, chemotherapy and radiotherapy, were retrieved from the database.
View Article and Find Full Text PDFHeterogeneity in response to neoadjuvant radiotherapy between soft tissue sarcoma histotypes: associations between radiology and pathology findings.
Eur Radiol
December 2024
Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Article Synopsis
- The study aimed to investigate imaging biomarkers for tumor response in patients with intermediate/high-grade soft tissue sarcomas (STS) following neoadjuvant radiotherapy (nRT), focusing on changes in imaging and pathology.
- The analysis involved 107 patients, measuring tumor characteristics like diameter, volume, and signal intensity before and after treatment, and correlated these with pathological outcomes such as necrosis and viable cell percentage using statistical methods.
- Results showed a low rate of complete tumor response, with specific subtypes like myxoid liposarcoma and undifferentiated pleomorphic sarcoma exhibiting significant changes in tumor size and signal intensity related to necrosis and fibrosis post-radiotherapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!